Crewe Advisors LLC Takes $29,000 Position in DexCom, Inc. (NASDAQ:DXCM)

Crewe Advisors LLC bought a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 210 shares of the medical device company’s stock, valued at approximately $29,000.

A number of other institutional investors have also recently modified their holdings of the stock. DSM Capital Partners LLC bought a new stake in shares of DexCom during the 4th quarter worth $28,000. Valley National Advisers Inc. lifted its position in shares of DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after buying an additional 103 shares during the last quarter. Riverview Trust Co bought a new stake in shares of DexCom during the 1st quarter worth $32,000. MV Capital Management Inc. lifted its position in shares of DexCom by 99.3% during the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after buying an additional 138 shares during the last quarter. Finally, Smithfield Trust Co lifted its position in shares of DexCom by 103.1% during the 4th quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock worth $40,000 after buying an additional 165 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

DXCM has been the subject of several recent analyst reports. Raymond James upped their price objective on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research report on Friday, April 26th. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a report on Monday, June 10th. Stifel Nicolaus lowered their target price on DexCom from $145.00 to $132.00 and set a “buy” rating for the company in a report on Friday, July 12th. Redburn Atlantic initiated coverage on DexCom in a report on Thursday, May 30th. They issued a “neutral” rating and a $130.00 target price for the company. Finally, Citigroup upped their target price on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and an average price target of $139.33.

DexCom Trading Down 3.7 %

NASDAQ DXCM traded down $4.09 during trading hours on Thursday, hitting $107.85. 10,917,461 shares of the company’s stock were exchanged, compared to its average volume of 2,908,776. The stock has a 50-day simple moving average of $116.63 and a 200 day simple moving average of $124.29. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00. The firm has a market cap of $42.89 billion, a price-to-earnings ratio of 69.58, a PEG ratio of 2.74 and a beta of 1.16. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The business had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. On average, equities analysts forecast that DexCom, Inc. will post 1.78 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Michael Jon Brown sold 659 shares of the firm’s stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $114.29, for a total transaction of $75,317.11. Following the completion of the sale, the executive vice president now owns 66,901 shares of the company’s stock, valued at $7,646,115.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other DexCom news, EVP Michael Jon Brown sold 659 shares of the stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $114.29, for a total value of $75,317.11. Following the transaction, the executive vice president now owns 66,901 shares in the company, valued at $7,646,115.29. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Bridgette P. Heller sold 1,000 shares of the stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $113.55, for a total value of $113,550.00. Following the completion of the transaction, the director now owns 25,349 shares in the company, valued at approximately $2,878,378.95. The disclosure for this sale can be found here. Insiders sold 4,112 shares of company stock valued at $480,861 over the last 90 days. Company insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.